FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for RETEVMO (selpercatinib) submitted by Eli Lilly and Company, expanding its approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ret Fusion-positive Solid Tumors
• Thyroid Cancer

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

SUPPL AP for RETEVMO (SELPERCATINIB)